No population-based study exists to demonstrate the full-spectrum impact of COVID-19 on hindering incident cancer detection in a large cancer system. Building upon our previous publication in JNCCN, we conducted an updated analysis using 12 months of new data accrued in the pandemic era (extending the study period from September 26, 2020, to October 2, 2021) to demonstrate how multiple COVID-19 waves affected the weekly cancer incidence volume in Ontario, Canada, and if we have fully cleared the backlog at the end of each wave.
Submitted August 29, 2022; accepted for publication September 15, 2022.
Disclosures: Dr. Eskander has disclosed receiving grant/research support from Merck and serving as a consultant for Bristol Myers Squibb. Dr. Hallet has disclosed receiving honoraria from Ipsen Biopharmaceuticals and Novartis Canada. The remaining authors have disclosed that they have not received any financial consideration from any person or organization to support the preparation, analysis, results, or discussion of this article.
Funding: This work was supported by a Sunnybrook Research Institute and Sunnybrook Foundation COVID-19 Response Grant and a Canadian Institutes of Health Research Operating Grant #179892.
Disclaimer: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Correspondence: Antoine Eskander, MD, ScM, University of Toronto, 2075 Bayview Avenue, M1-102, Toronto, Ontario, Canada M4N 3M5. Email: email@example.com
GuvenDC, SahinTK, YildirimHC, Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality. BMJ Support Palliat Care. doi: 10.1136/bmjspace-2021-00330134711656)| false